PROVECTUS BIOPHARMACEUTICALS, INC. Debt Conversion, Converted Instrument, Amount
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported Debt Conversion, Converted Instrument, Amount of $1.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-08-13
- PROVECTUS BIOPHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2026-06-30 was $583.43K.
- PROVECTUS BIOPHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2026-03-31 was $491.50K.
- PROVECTUS BIOPHARMACEUTICALS, INC. debt conversion, converted instrument, amount for fiscal 2022 was $1.26M, a 94.98% decline from fiscal 2021.
- PROVECTUS BIOPHARMACEUTICALS, INC. debt conversion, converted instrument, amount for fiscal 2021 was $25.09M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|
| 2026-06-30 | $583.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.07M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $491.50K 10-Q · filed 2026-05-14 | ||
| 2022-12-31 | $1.26M 10-K · filed 2023-03-30 | ||
| 2021-12-31 | $25.09M 10-K · filed 2023-03-30 |